Article

Versatility key feature of upgraded keratome

Analyses of flap thickness showed favorable predictability.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
Related Content
Nanoscope Therapeutics initiates rolling submission of BLA to FDA for MCO-010
July 14th 2025

Nanoscope Therapeutics initiates rolling submission of BLA to FDA for MCO-010

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis
July 14th 2025

Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Navigate successful cataract surgery with refractive technology
July 11th 2025

Navigate successful cataract surgery with refractive technology

LIGHTHOUSE study of ATSN-201 expanded to continuous phase 1/2/3 trial following FDA feedback
July 11th 2025

LIGHTHOUSE study of ATSN-201 expanded to continuous phase 1/2/3 trial following FDA feedback

© 2025 MJH Life Sciences

All rights reserved.